A range of therapeutic agents that inhibit myostatin signaling are currently being tested in clinical trials for a number of indications34, the outcomes of which will provide the opportunity to design clinical trials to treat muscle atrophy in people affected with HD. Here, MSTN is linked to Huntington disease.